Drug Trial Radar · NCT04358406
Rhu-pGSN for Severe Covid-19 Pneumonia
Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jul 30, 2020
Primary completion
May 25, 2021
Study completion Jan 28, 2022
Sponsor
- Lead sponsor
- BioAegis Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Objectives: Primary * To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5 or 6 on the World Health Organization (WHO) 9-point severity scale * To evaluate the safety and tolerability of three IV doses of rhu-pGSN administered to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5, or 6 on the WHO 9-point severity scale Secondary * To further assess the efficacy of IV administered rhu-pGSN * To assess changes in WHO 9-point severity score for SOC with or without rhu-pGSN * To evaluate the effect of administered rhu-pGSN on survival rates * To assess the relationship of pGSN levels (and other biomarkers) at baseline with clinical outcomes * \[OPTIONAL\] To follow the pharmacokinetics (PK) of administered rhu-pGSN Immunogenicity • To investigate the development of antibodies against rhu-pGSN post-treatment
Conditions
- Sars-CoV2
Interventions
Recombinant human plasma gelsolin (Rhu-pGSN)Drug
Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
PlaceboOther
Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or DialysisTime frame: Day 14
- Safety: Number of Subjects With SAEsTime frame: Day 1 through Day 90
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie
Timișoara, Romania
Sant Joan de Reus SAM University Hospital
Reus, Spain
Hospital Universitari de Tarragona Joan XXIII
Tarragona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.